An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3624-3632

  Mishima, Yuji ^a   Sugimura, Natsuhiko ^a,c   Matsumoto Mishima, Yuko ^a   Terui, Yasuhito ^a   Takeuchi, Kengo ^b   Asai, Suzuka ^a   Ennishi, Daisuke ^a   Asai, Hiroaki ^a   Yokoyama, Masahiro ^a   Kojima, Kiyotsugu ^c   Hatake, Kiyohiko ^a,b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c OLYMPUS CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; EX VIVO STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPH NODES; LYMPHOCYTES; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; ROC CURVE; TREATMENT OUTCOME;

EID: 66149185427     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1536     Document Type: Article

References (23)

1. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-3908 (Pubitemid 30412866)
2. Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006;34:753-759 (Pubitemid 43737097)
3. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev 2003;17:25-31. (Pubitemid 36181503)
4. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti- CD20 reagents. Blood 2004;103:2738-2743 (Pubitemid 38393032)
5. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non- Hodgkin's lymphomas. Clin Cancer Res 2005; 11:5971-5980 (Pubitemid 41170328)
6. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-1319 (Pubitemid 34547086)
7. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{γ}RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-2564 (Pubitemid 47523179)
8. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474-481 (Pubitemid 46224224)
9. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab- dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-4669 (Pubitemid 38856941)
10. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-758 (Pubitemid 34525533)
11. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003;21:1466-1471 (Pubitemid 46594097)
12. Terui Y, Sakurai T, Mishima Y, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006;97:72-79 (Pubitemid 43257030)
13. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-641 (Pubitemid 30353375)
14. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12: 4027-4035 (Pubitemid 44078090)
15. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-1043 (Pubitemid 34525569)
16. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 2007;178: 2287-2295 (Pubitemid 46233427)
17. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21: 3940-3947 (Pubitemid 46606207)
18. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-459 (Pubitemid 36278014)
19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446 (Pubitemid 30208162)
20. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non- Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708 (Pubitemid 27260903)
21. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171: 1581-1587 (Pubitemid 36900094)
22. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811 (Pubitemid 34042897)
23. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001;98:1352-1357